Tralokinumab-ldrm (Adbry) Autoinjector Now Available for the Treatment of Adults With Moderate-to-Severe AD in the U.S.
Tralokinumab-ldrm (Adbry, LEO Pharma Inc.) is now available as a 300mg/2mL single-dose autoinjector in the United States. Tralokinumab-ldrm is currently indicated in the U.S. for patients 12 years and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Prior to the […]